RG 7625

Drug Profile

RG 7625

Alternative Names: RG7625; RO 5459072

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome
  • Phase I Autoimmune disorders; Coeliac disease

Most Recent Events

  • 10 Jul 2017 Roche completes a phase II trial in Sjogren's syndrome in USA, United Kingdom, Portugal, Poland, Germany, France (PO) (NCT02701985)
  • 01 Aug 2016 Roche completes a phase-I trial in Coeliac disease in United Kingdom (PO) (NCT02679014)
  • 01 May 2016 Phase-II clinical trials in Sjogren's syndrome in USA (PO) (NCT02701985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top